Promising research suggests CBD could help beat back an aggressive cancer
Early-stage cell studies point to another way CBD could become medicine.
CBD is as trendy for dogs as it has been for humans. With the hype that touts the cannabinoid as a cure-all, it’s easy to forget that CBD has serious medical clout.
According to new research, it now shows promise in combating one of the most serious medical issues for both people and pets: glioblastoma, a common and often-deadly form of brain cancer.
Gliomas are tumors that often occur in the brain or spinal cord, and begin in glial cells вЂ“В “gluey” cells that, when functioning normally, surround neurons and help them function. It’s estimated that gliomas make up about 30 percent of all brain tumors, and 80 percent of malignant tumors (which are the ones that are cancerous).
Gliomas can be extremely aggressive. The survival rate for patients with malignant brain tumors is about 36 percent according to the National Brain Tumor Society.
A study released Monday, based on results from human and canine cells, suggests that CBD could effectively be used alongside other cancer treatments because of its ability to disrupt how cancer cells function.
CBD can slow cancer growth because it causes the mitochondria in cancer cells to dysfunction, the study reports. Mitochondria is what allows the cells to produce energy, and keep living.
This study has not been published in a journal, but would have been presented at the 2020 Experimental Biology conference (it has been canceled due to the coronavirus).
Chase Gross is the study’s first author and a student at Colorado State University’s Doctor of Veterinary Medicine program. He suggests that these results may lead to improved cancer treatments for both humans and our pets, who also suffer from brain tumors as well.
“CBD has been zealously studied in cells for its anticancer properties over the last decade,” Gross explains. “This could lead to new treatments that would help both people and dogs that have this very serious cancer.”
For dogs, brain tumors are responsible for about 2 percent of deaths. They tend to appear in long-nosed dogs, like Golden Retrievers but are also common in Boston Terriers, French Bulldogs, Boxers, Doberman Pinschers, Scottish Terriers, and Old English Sheepdogs.
Importantly, CBD cannot be used to treat cancer. This distinction is important: The CBD industry is rife with false or unproven claims about what it can actually do. The FDA is is “increasingly concerned” about cannabis products that falsely claim to shrink tumors or treat cancer.
Past studies have suggested that cannabinoids, like CBD, may have anti-tumor effects, but these are largely dependent on the type of cancer and the dosage in question. For glioblastoma, past research suggests that CBD can mess with various molecular pathways that tumors use to thrive.
Here, CBD is described as a “synergistic glioblastoma therapy option,” meaning it could potentially be used in tangent, and boost, other forms of treatment.
Gross and his colleagues tested the effect of a pure CBD isolate and another form of CBD that had minimal amounts of THC and other cannabinoids. On its own, CBD was both cytotoxic (meaning it killed some cells), and stopped other cells from proliferating.
However, the concentrations of CBD needed to achieve those effects were “not pharmacologically possible” the authors write. Crucially, this study is an early step towards proving CBD’s effectiveness.
Still, the team found that, even in lower concentrations, CBD was able to mess with mitochondria. Ultimately, they argue that CBD causes the mitochondria to release reactive oxygen species which can cause DNA damage or cell death.
It also appeared to create large, swollen vesicles inside the cell that were the precursors of a breakdown in the cell.
Taken together, this suggests CBD sets off the cancer cell’s internal “self-destruct” functions (also called apoptosis or programmed cell death).
Before this work can go any further, the team will need to scale up animal testing, likely, in dogs.
But these results, as Gross notes, may present a path forward. In 2020, an estimated 87,240 people may receive a brain tumor diagnosis. These results represent one of many ways scientists are searching for solutions beyond what we already have. While there is no cure for glioblastoma, there are treatment options. In the future, these might be paired with CBD.
Abstract: The use of cannabidiol (CBD), the major non-psychoactive compound derived from cannabis, as a nutraceutical in both human and veterinary medicine has increased steadily within the past ten years despite a lack of scientific evidence for its effectiveness. Of the cornucopia of ailments that CBD supposedly treats, epilepsy, pain, and cancer remain prominent areas of interest to scientists and the general public. In the world of cancer research, several publications have demonstrated that CBD is cytotoxic against breast, endometrial, glial, and blood cancers, and in all cases it appears that CBD triggers apoptosis through a cannabinoid receptor independent process. A recent publication suggests CBD causes cell death in leukemia cells via calcium dependent mitochondrial membrane disruption, leading to activation of intrinsic apoptosis. Other receptors, such as TRPV1, and pathways, such as autophagy, have been implicated in CBD-induced cell death but the molecular details remain elusive. Because of their remarkable similarities, from a comparative oncology perspective, canine and human gliomas are of particular interest. Regardless of species, gliomas are aggressive tumors that are notoriously challenging to treat, given their resistance to multimodal treatment, thus creating a need for more effective therapeutics. We sought to characterize the mechanism of CBD-induced cell death in both human and canine glioma cells. We show that CBD by itself is cytotoxic, anti-proliferative, and anti-migratory but at concentrations which may not be pharmacologically attainable. Using resazurin and the IncuCyte live cell imaging platform, we show that metabolic-based assays artificially increase cell line sensitivity to CBD compared to the IncuCyte, suggesting that non-cytotoxic concentrations of CBD perturb mitochondrial function. Furthermore, we show that CBD treatment results in the formation of large cellular structures whose existence are RIPK3-dependent. After treatment with a variety of cell death inhibitors, we demonstrate that CBD-induced cell death occurs via apoptosis; a classically necroptotic protein, RIPK3, also appears to be involved. Lastly, by combining CBD with the autophagy inhibitor hydroxychloroquine (HCQ) we show that sensitivity to CBD increases with HCQ treatment in canine cells, which suggests involvement of the autophagy pathway for mediating CBD-induced cell death. These data demonstrate that human and canine glioma cells respond similarly to CBD, indicate a non-canonical function of RIPK3, and support the involvement of autophagy in CBD-induced cell death.
CBD is not currently a treatment for cancer. But scientists are performing early-stage research to investigate how it could be used to treat cancerous cells.
Cannabis is the dried preparation, or resinous extract, of the flowers or leaves of the cannabis plant, a member of the hemp family. It is an illegal drug in many countries, including the UK.
The parts of cannabis that are considered important for medical reasons are called cannabinoids. This is the name for the complex chemicals found in cannabis that are responsible for the effect cannabis has on the body. Two cannabinoids are of particular interest:
- THC – delta-9 tetrahydrocannabinol (responsible for the psycho-active and addictive effects of cannabis)
- CBD – cannabidiol
It’s important to make clear the difference between cannabis, cannabis oil and CBD oil.
Cannabis and cannabis oil
Cannabis and cannabis oil are classified as a class B drug in the UK, because they contain the component THC. It is illegal to possess or supply them. However, from 01 November 2018, cannabis-based products for medicinal use will be available in the UK in some circumstances only.
Only specialist doctors who are listed in the General Medical Council’s (GMC) specialist register will be able to prescribe cannabis-based products. They will only be prescribed when the specialist considers that the patient will benefit and when the patient has an unmet special clinical need that cannot be met by licensed products.
- Medicinal cannabis, therefore, will be prescribed on a case-by-case basis
- Patients will NOT be able to get cannabis-based products from their GP
- If you feel you might benefit from these products, speak to your consultant or healthcare team
- Administration by smoking remains prohibited.
(For more information, see our blog on cannabis-based medicinal products.)
CBD oil is different from cannabis oil, because it does not contain THC.
It is currently legal in the UK – as long as it has been produced from an EU approved strain of hemp and as long as it is marketed as a food supplement without any medicinal claims. You can buy it in many high street health food shops.
Get your free Information Pack
Our Brain Tumour Information Pack can help you better understand your diagnosis and feel confident talking to your medical team.
What is the evidence for cannabis-based products in the treatment of brain tumours?
Treating the side-effects of a brain tumour
There’s now conclusive evidence for the use of cannabis and its products, such as cannabis oil and CBD oil, for other therapeutic purposes, i.e. pain relief and treating chemotherapy-induced nausea and vomiting.
As such, the cannabis-based drug, Nabilone, has a medical licence and can be legally prescribed for chemotherapy-induced nausea and vomiting.
Treating the brain tumour itself
Currently, the evidence that cannabis-based products can treat brain tumours themselves is limited.
There have been some promising pre-clinical trials in mice, in which THC, CBD and radiotherapy used together appeared to slow tumour growth. More research involving clinical trials in people needs to be done.
There have also been some positive results using a drug called Sativex (a combination of THC and CBD) alongside the chemotherapy drug temozolomide (TMZ). It was found that in people with recurrent glioblastoma, those treated with Sativex had a higher chance of longer survival time, compared to those who didn’t have the drug.
However, it was a small trial, on only 21 patients, to test the safety and effectiveness of using Sativex. The next stage will be to look at whether Sativex works better than standard treatment or whether it produces fewer side-effects. Although a large amount of progress has been made, it could be up to another five years before this drug is licensed for use in brain tumour patients.
How can I get cannabis-based products?
Speak to your healthcare team.
Apart from the special circumstances described earlier above, and the prescribing of Nabilone for chemotherapy-induced nausea and vomiting, it might be possible for Sativex to be accessed via off-label prescribing.
Off-label prescribing is where your doctor can prescribe a drug licenced for another condition, if they feel it would benefit you and there is no other licensed treatment or all licensed treatments have failed. Sativex is licensed for the treatment of spasticity (tightening of the muscles) in multiple sclerosis.
However, many doctors may be reluctant to prescribe off-label as the responsibility for the prescribing and any adverse effects, lies with them. Also the professional codes, ethics and prescribing policies of their hospital trust may prevent it. You can always speak to your doctor about this.
Some people affected by a brain tumour may decide to self-medicate with cannabis.
We would always recommend that any supplements, alternative or complementary treatments that you/your loved one wishes to use are discussed with your/their medical team. This is because it may, for example, interact with other medications, such as anti-epileptic medicines, steroids or chemotherapy.
It is important to be aware that you cannot be sure of the concentrations and ratios of THC and CBD in grown or street cannabis.
If you need someone to talk to or advice on where to get help, our Support and Information team is available by phone, email or live-chat.
- Getting a second opinion
- Clinical trials
- If a treatment doesn’t work
Share your experiences and help create change
By taking part in our Improving Brain Tumour Care surveys and sharing your experiences, you can help us improve treatment and care for everyone affected by a brain tumour.
If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:
Support and Information Services
0808 800 0004 (free from landlines and mobiles)
Phone lines open Mon-Fri, 09:00-17:00
Research & Clinical Trials Information
You can also join our active online community – Join our online support groups.
There’s conclusive evidence for the use of cannabis and its products, such as cannabis oil and CBD oil, for other therapeutic purposes.